Skip to Content
MilliporeSigma
All Photos(1)

Documents

V4758

Sigma-Aldrich

Monoclonal Anti-Vascular Endothelial Growth Factor antibody produced in mouse

clone 26503, purified immunoglobulin, lyophilized powder

Synonym(s):

Anti-VEGF

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
51111800
NACRES:
NA.41

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

26503, monoclonal

form

lyophilized powder

species reactivity

primate, human

technique(s)

capture ELISA: 2-8 μg/mL
neutralization: suitable
western blot: 1-2 μg/mL

isotype

IgG2b

UniProt accession no.

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

General description

The antibody will neutralize the biological activity of recombinant human VEGF165. It also recognizes VEGF121.

Immunogen

purified recombinant Sf21-derived human VEGF (165 aa isoform).

Application

Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Monoclonal Anti-Vascular Endothelial Growth Factor antibody produced in mouse was used to block the interaction between VEGF and kinase domain receptor in Calf Pulmonary Aortic Endothelial (CPAE) cells.

Biochem/physiol Actions

The vascular endothelial growth factor family consists of five members, VEGF-A to VEGF-E. They play important roles in important role in embryonic vasculogenesis, angiogenesis and homeostasis. The interaction between VEGFs and their respective receptors results in the activation of MAPK, PI3K, PKC, FAK and Src kinase pathways.

Physical form

Lyophilized from a 0.2 μm solution in phosphate buffered saline containing carbohydrates.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Esther Grueso et al.
Journal of virology, 93(19) (2019-07-19)
As many tumor cells synthetize vascular endothelial growth factors (VEGF) that promote neo-vascularization and metastasis, frontline cancer therapies often administer anti-VEGF (α-VEGF) antibodies. To target the oncolytic parvovirus minute virus of mice (MVM) to the tumor vasculature, we studied the
A Ohwada et al.
Thorax, 58(4), 328-332 (2003-04-02)
Acid induced pneumonitis resulting in acute respiratory distress syndrome (ARDS) is characterised by increased alveolar permeability and accumulation of neutrophils. It is hypothesised that vascular endothelial growth factor (VEGF) is involved in the development of lung oedema. Furthermore, lower levels
Dong-Kwon Lim et al.
Biomaterials, 77, 130-138 (2015-11-21)
Vascular endothelial growth factor 165 (VEGF165) is an important extracellular protein involved in pathological angiogenesis in diseases such as cancer, wet age-related macular degeneration (wet-AMD) and retinitis pigmentosa. VEGF165 exists in two different isoforms: the angiogenic VEGF165a, and the anti-angiogenic
R Binétruy-Tournaire et al.
The EMBO journal, 19(7), 1525-1533 (2000-04-04)
Vascular endothelial growth factor (VEGF) binding to the kinase domain receptor (KDR/FLK1 or VEGFR-2) mediates vascularization and tumor-induced angiogenesis. Since there is evidence that KDR plays an important role in tumor angiogenesis, we sought to identify peptides able to block
Chiara Sassoli et al.
Experimental physiology, 107(2), 106-121 (2021-12-23)
What is the central question of this study? It is a challenge to discover effective therapies for fibrosis. Increasing evidence supports the antifibrotic potential of platelet-rich plasma (PRP) as a source of bioactive molecules, such as vascular endothelial growth factor

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service